Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid - Wikidata - wikimedia - TriplyDB

Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid

Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid

http://www.wikidata.org/entity/Q34699437

about

Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Alzheimer Disease Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.NG2 cells, a new trail for Alzheimer's disease mechanisms?Outcome markers for clinical trials in cerebral amyloid angiopathy.The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study.Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment.Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease A consensus in Korea regarding a protocol to reduce preanalytical sources of variability in the measurement of the cerebrospinal fluid biomarkers of Alzheimer's disease.Emerging β-amyloid pathology and accelerated cortical atrophy.Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects.Shapes of the trajectories of 5 major biomarkers of Alzheimer disease Recent advances in neuroimaging biomarkers in geriatric psychiatry.Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study.β-amyloid dynamics in human plasma Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults.Cerebral amyloid PET imaging in Alzheimer's disease.Biomarker modeling of Alzheimer's disease.Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians.Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment.Biomarker modelling of early molecular changes in Alzheimer's disease.Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians.Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration.The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.

P2860

Q24594531-92324D5A-DE8C-4017-97F5-591E46BDE8B2 Q26749755-1F6A1C0E-7917-4723-A87D-C0A9E2E569AA Q26784569-D9834084-BFBF-499C-B09D-9CBA433E5565 Q26801629-10CC971F-79E2-4C38-8E8E-B7EC11A1E96A Q27006831-2A0B584B-2F4C-4532-B8D4-6FACD03A3559 Q27007436-B1D4BD71-44E1-4762-A5D0-0102499B2458 Q28273817-F1E175E8-F639-424E-806F-55F9C99CC406 Q30971403-9D28641F-6914-4E84-BA42-44017C8212FA Q33562441-42EA50BB-8E01-4E40-BC00-AE4F92B71FCA Q33604453-37F21EEF-CE47-47B3-BD6D-8A91F8D3966E Q33715573-84186967-EC1F-4F34-A153-9536CA8A632F Q33859442-D743BF00-5997-4132-9B6A-3220D1705530 Q34065449-D564133F-534A-480D-96FD-A9C3363DB6BF Q34286393-AE014E87-C5DE-44DB-AEE9-E1B2EB6FDD05 Q34341870-FF0A46BB-814B-4A43-8097-B177CD3370DB Q34462406-861AA5C8-8508-4C13-B3CC-14BCEABFF2EC Q34493453-459F5588-2B75-40F8-AAAF-616AAFBEC491 Q35106592-7FA308FB-7E76-4CDE-98CC-E8EC99F55349 Q35119389-F053619A-7397-4A91-BD09-543075336B58 Q35291150-5057ED8A-81A9-4A8B-BB72-ABCED0CBE620 Q35542164-BFC66080-7929-4CAB-9E57-5502BF6A1125 Q35821382-3127DB54-2429-4C47-A44A-A9177FD8B857 Q35948528-6DDECCF7-C481-4589-89F7-A79017B42CE9 Q36407301-74A6FF72-A7A0-437F-9D6D-311E7134662F Q36677361-0462D575-0FE0-450D-B3E0-38B361DB72FC Q36885496-8E495E1A-687A-4CE6-A5D8-82D75265F299 Q36998414-CE11F1C0-4CB4-4C6A-84B0-1263C13663FE Q37107044-8FAB3828-E661-48B0-9A3F-DACDB9A79852 Q37198556-2652325D-72BC-49C3-85FE-9C102691F5D2 Q37254727-8D68859F-D129-418E-B297-BFB8065B2552 Q37395886-7702FEC4-03B1-43AB-8577-D0DFBD51C16B Q37459083-29934F38-A0F1-4FE8-9D92-2524A4A3F948 Q37592824-0CB5737E-CE52-43AC-84B1-0FE464E31A0D Q37693146-A5DAFF69-3E18-45C8-A301-948488B9287C Q37976853-51562EF0-27B6-4FCA-92AA-1E71E9E3698F Q38166669-BED8DD1A-FF93-4FB6-80FC-1E4CB7F30FD1 Q38269095-D1D75995-B24B-4FCC-8359-C87337A86051 Q41140682-2AA2521E-2D79-486E-929A-F5ACE784E0B6 Q41178085-09CF2F78-BD7F-472D-8A64-2BF1E8231758 Q42363366-E85901DB-E0C4-421D-B5C1-FAD0798741CC

P2860

Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid

http://www.wikidata.org/entity/Q34699437

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Transforming cerebrospinal flu ...... nd B units of brain Aβ amyloid

@ast

Transforming cerebrospinal flu ...... nd B units of brain Aβ amyloid

@en

Transforming cerebrospinal flu ...... nd B units of brain Aβ amyloid

@nl

type

label

Transforming cerebrospinal flu ...... nd B units of brain Aβ amyloid

@ast

Transforming cerebrospinal flu ...... nd B units of brain Aβ amyloid

@en

Transforming cerebrospinal flu ...... nd B units of brain Aβ amyloid

@nl

prefLabel

Transforming cerebrospinal flu ...... nd B units of brain Aβ amyloid

@ast

Transforming cerebrospinal flu ...... nd B units of brain Aβ amyloid

@en

Transforming cerebrospinal flu ...... nd B units of brain Aβ amyloid

@nl

P1433

Q34699437-37FC1ACB-FCC4-467C-896B-6B33863AD6F5

P1476

Q34699437-C061DEEE-DB72-42E0-94DF-10E9F2AF3B4D

P2093

Q34699437-0209029C-4E97-4DFD-882E-93FA685FCCF5

Q34699437-1F34BF5E-F4AE-4025-9948-67E6FD18C723

Q34699437-23459B59-3D1F-41BB-987F-6DF61E8F1D6B

Q34699437-449A96A3-1482-4D6C-93FD-E70357947739

Q34699437-B593FB7C-D01F-4939-834D-E9474A6A66C4

P2860

Q34699437-08AB2409-D527-4F7F-BCB9-9E46D217A6CE

Q34699437-0EE3EAE9-49CD-42CC-9B83-5337CD844616

Q34699437-10B6928F-422F-410C-8A3F-D7A675A38188

Q34699437-15466B4B-88AD-4FD4-8096-57996F11895B

Q34699437-19BB90E7-BC5F-4D7D-ABB3-B40C4C4AC43A

Q34699437-213FF6EC-EAFC-491F-939D-F9973ECF3232

Q34699437-345D62C4-C9B8-4174-BE10-D0EBA80259CC

Q34699437-3830AD55-D591-4FE6-A0F1-91176B32B90E

Q34699437-39A5AAD9-047C-4704-9DE2-60ECB9BEAFD4

Q34699437-3EE3AA5A-AF5A-4A9E-9FD3-0B1CAC208E2F

P304

Q34699437-DB824C88-DE1A-44A5-B9AA-B8CD14345056

P31

Q34699437-24592F97-E63B-4772-A142-42A1C8BA9582

P356

Q34699437-4B2D496F-241B-41D9-864D-16284D4D69D1

P407

Q34699437-BA3B6904-675E-43CF-B5E3-4DE1B42054DD

P433

Q34699437-3FA8002C-0120-4309-9D0D-3E5625AD3892

P478

Q34699437-84FE46DB-63E7-4271-8B7B-F9271898D996

P50

Q34699437-483319D5-F7EF-46DF-BB0A-7306BF33E5D2

Q34699437-4FBA1BAE-7C10-43CD-9115-152FA1B5678E

Q34699437-5D185133-22AE-45C9-9B8E-F367AAF11961

Q34699437-7D8BB194-5079-46B8-9068-2F90F86AD7DC

Q34699437-94AC6433-D1BA-465D-B4B7-97A1F7AE09D9

Q34699437-CCD63453-F965-412B-89F7-A07A48A62663

Q34699437-FA733984-A383-483D-AD8F-C68D86C9E03C

Q34699437-FE6DAA16-EE14-4320-8D8C-852026117CF0

P577

Q34699437-C7B3E04A-5C07-41E5-9C0F-F9A707174690

P5875

Q34699437-B0B1F2C5-884A-4F3D-BCB3-AD2ADC29EA83

P698

Q34699437-81A27E1B-A302-4DD4-92E3-1581EF70B9BC

P921

Q34699437-947AB722-30D4-4140-821D-9EDA84ED26F9

P932

Q34699437-1B95228D-38F6-47D0-9C0C-78A195D9CADC

P356

J.JALZ.2010.08.230

P1433

Alzheimer's and Dementia

P1476

Transforming cerebrospinal flu ...... nd B units of brain Aβ amyloid

@en

P2093

Heather J Wiste

http://www.w3.org/2001/XMLSchema#string

Leslie M Shaw

http://www.w3.org/2001/XMLSchema#string

Prashanthi Vemuri

http://www.w3.org/2001/XMLSchema#string

Stephen D Weigand

http://www.w3.org/2001/XMLSchema#string

Vernon S Pankratz

http://www.w3.org/2001/XMLSchema#string

P2860

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain

Statistical methods for assessing agreement between two methods of clinical measurement

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

Serial MRI and CSF biomarkers in normal aging, MCI, and AD

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

P304

133-141

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JALZ.2010.08.230

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Matthew L Senjem

Alzheimer's Disease Neuroimaging Initiative

Ronald C. Petersen

Michael W. Weiner

John Q. Trojanowski

David S Knopman

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49799161

http://www.w3.org/2001/XMLSchema#string

P698

21282074

http://www.w3.org/2001/XMLSchema#string

P921

cerebrospinal fluid

P932

3060961

http://www.w3.org/2001/XMLSchema#string